Company intelligence / Profile preview

Cirqle Biomedical

Copenhagen, Denmark

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Cirqle Biomedical's lead program is a pre-clinical, first-in-class non-hormonal, on-demand contraceptive candidate that aims to reinforce cervical mucus with a topically applied biopolymer, creating a temporary barrier against sperm transport. It has demonstrated encouraging preclinical results and is partnered with Organon for global development and commercialization rights.

Therapeutic areas: Women's Health
Modalities: DeviceBiopolymer-based therapy
Industry: Biotech

Partnerships

Organon (exclusive global license for lead asset)

Beyond the preview

Go deeper on Cirqle Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cirqle Biomedical.

Explore the full profile